Rationale: MyomiRs miR-499, miR-208a and miR-208b direct cardiac myosin gene expression. Sequence complementarity between miRs and their mRNA targets determines miR effects, but the functional consequences of human myomiR sequence variants are unknown.
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Interactions between miRs and their target mRNAs are determined by miR abundance, mRNA target abundance, and miR-mRNA binding affinity; the latter is determined largely by binding site and miR sequence complementarity. There is tremendous variation in binding site sequence for a given miR within and between different mRNA targets. In contrast, nucleotide sequence for a given miR is highly conserved across species and between individuals. 4 We postulated that naturally occurring variation in mature miR sequences might have pathophysiological impact by creating new miR family members, thus altering suppression of target mRNAs with binding site nucleotides complementary either to the wildtype or mutant miR. In vivo data relating the effects of miR sequence variation on mRNA targeting function and endorgan phenotype are currently lacking.
To test the notion that miR mutations will alter in vivo heart function, we elected to study highly expressed cardiac miRs with well-established end-organ effects. The myomiR family of muscle-specific miRs coordinately regulate cardiac myosin isoform expression. [5] [6] [7] MyomiRs are reportedly regulated in human heart failure as part of a broader genetic program involving dozens of miRs and mRNAs, 8, 9 and forced cardiac-specific miR-499 expression at levels seen in human heart failure induces progressive cardiac enlargement and contractile dysfunction, ie, dilated cardiomyopathy, in normal and pressure-overloaded hearts. 10 Here, we used pooled sequencing of a diverse cohort of human DNA samples to discover a novel, rare human miR-499 mutation that is within the mature miR sequence, but outside the 5Ј seed region considered to be the major determinant of mRNA target recognition. Using in vitro assays of miR function to direct genome-wide in vivo molecular RNA proteomics analyses and computerized modeling of miR-mRNA duplex structures, we demonstrate that this 3Ј extra-seed sequence miR-499 mutation conditionally changes miR-499 target mRNA recognition, thereby altering the effects of miR-499 on the cardiac transcriptome and proteome and modifying characteristics of the cardiomyopathy conferred by miR-499 overexpression. These findings strongly support further genome-wide efforts for discovery and in vivo analysis of potentially pathological human miR sequence variants.
Methods

Pooled Resequencing of Human Genomic DNA
Genomic regions containing miR precursors were analyzed in 1742 individuals of Caucasian descent and 864 of African-American descent, using massively parallel sequencing of pooled samples, as previously described. 11, 12 
Luciferase Reporter Studies
Three tandem copies of the nucleotide sequence perfectly complementary to wild-type miR-499, or mutant miR-499 c17, were cloned into pmiRGLO (Promega). Similar techniques were used to generate sequences containing single or double nucleotide changes in the binding site complementary to seed sequence positions 6 (⌬6) or 3 and 4 in combination (⌬3,4). The miR-499 cDNA encoding the pri-miR was cloned from human DNA into pcDNA3.1 (Invitrogen) and mutations were engineered using site-directed mutagenesis (Stratagene QuikChange). Pri-miR and reporter constructs were transfected in sextuplicate into HEK293 cells using Fugene HD (Promega). Firefly 3ЈUTR-coupled luciferase activity was normalized to constitutive Renilla luciferase activity for each well. The 3Ј UTRs of Sox6, Pdcd4, and Skil were cloned into psiCheck2 (Promega) and assayed similarly. Saturation mutagenesis of the complementary miR-499 sequence was performed via ligation of doublestranded oligonucleotides directly into pmiRGLO.
Animals
The miR-499 transgenic mice were generated by cloning a 530-bp fragment flanking mouse miR-499 (chromosome 2, intron 19 of Myh7b) into the cardiac-specific mouse Myh6 promoter construct. The wild-type miR-499 mouse (designated line 1, expressing at 16-fold normal levels) is described elsewhere (Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn GW II, unpublished data, 2012). The mutant miR-499 mouse (line 2, expressing at 23-fold normal levels) was chosen for comparative study because it expresses mature miR-499 in heart at levels similar to that of the wild-type miR-499 transgenic mouse and to human heart disease (Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn GW II, unpublished data, 2012). Mice were generated and housed according to procedures approved by the Washington University Institutional Animal Care and Use Committee.
Transcriptional and RISC mRNA Profiling by High-Throughput Sequencing
Preparation of cDNA fragments from poly(Aϩ)-selected cardiac RNA was as previously described. 13 Conditions for Ago2 immunoprecipitation and isolation of bound RNA from mouse hearts were adapted from Karginov et al, 14 as described by Matkovich et al. 13 Preparation of bar-coded Illumina sequencing libraries, sorting by barcode, and transcriptome mapping were performed as previously described. 15
Proteomics
Three-color, 2-dimensional DiGE (differential in-gel electrophoresis) analyses of 5 paired hearts (miR-499 wild-type versus miR-499 mutant) were performed at Applied Biomics (Hayward, CA) as described. 16 
Molecular Modeling
Molecular modeling of miR-499 mRNA duplexes used RNAhybrid 17 (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/) to predict binding energies (minimum free energy of hybridization, mfe) associated with various miR-mRNA sequence mismatches and their corresponding multipli-iterative.
Results
A Human miR-499 Nonseed Sequence Mutation Alters in Vitro Target mRNA Suppression
Some naturally occurring miR sequence variations are predicted to impact mRNA targeting. 18 Although it is possible to explore the impact of binding site sequence variation on miR-mRNA interactions using mutagenesis, this approach lacks direct translational applicability to the human condition. On the other hand, little is currently known about the prevalence and pathophysiology of human miR sequence variation. Thus, we screened Ϸ2600 human DNA samples for sequence variation corresponding to the pre-miRs for each of the 3 human myomiRs, miR-208a, miR-208b, and miR-499. Figure 1A graphically displays the position and frequency of sequence variations detected. MyomiR sequence variants were common in DNA corresponding to the primary intronic miRs and the precursor miR (the Drosha-processed stem-loop structure 1 ) (Online Table  I ), but only 1 myomiR sequence variant occurred within the mature miR, a rare C substitution for T at nucleotide (nt) 17 of miR-499 identified in 2 DNA samples ( Figure 1A , red arrow, and Online Table I ). Two previously reported common miR-499 precursor single nucleotide polymorphisms (SNPs) were also detected, rs3746444 and rs7267163 ( Figure 1A and 1B). The former is located at nucleotide position 5 of miR-499* (aka miR-499 -3p), the double-stranded complement to mature miR-499 (aka miR-499 -5p), which is degraded during processing and has no known biological effect on the heart. All 3 of these miR-499 sequence variants were confirmed by Sanger sequencing ( Figure 1B) .
The novel miR-499 c17 mutation was detected in 2 of the 2600 DNA samples. Nonseed sequence miR mutations are
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not generally considered to meaningfully impact miR function. 2, 19 A genetic approach to determine whether miR-499 c17 affects the clinical status of the 2 human subjects in which it was identified was not possible because the number of affected individuals is too small to derive a statistically robust genotype-phenotype relationship; family pedigrees were not available. We considered, however, that a detailed functional and biological analysis of the miR-499 c17 mutation could establish whether this mutation has any effect on mRNA targeting, and test for the first time the conventional wisdom that extra-seed sequence miR variation does not impact human health or disease. Initial functional studies were designed to test whether the miR-499 c17 nucleotide mutation has any functional impact under the most rigorous conditions, ie, when all of the other miR-mRNA binding sites are perfectly matched. Accordingly, we designed luciferase reporter constructs with artificial binding site sequences exactly complementary to either the wild-type or mutant miR. This approach assays the potential for both loss of function (eg, when the mutation introduces a binding pair mismatch at position 17) and gain of function (eg, when the mutation corrects a mismatch at the same position). Overall luciferase suppression was 80% to 90% for both targets by wild-type (u17) and mutant (c17) miR-499, and each miR-499 suppressed its perfect complement to a significantly greater degree than it did the binding site with a single mismatch at position 17 (Figure 2A ). By contrast, suppression of artificial mRNA target sites with single or double seed sequence mismatches (⌬6 and ⌬3,4) was only Ϸ20% by either c17 or u17 miR-499; there were no significant differences between wild-type and mutant miR-499 when binding site seed-sequence complementarity was disrupted ( Figure 2A ). The 2 miR-499 precursor polymorphisms that did not change mature miR-499 sequence had no effect on luciferase reporter activity (Online Figure I) . These results show that the miR-499 seed region plays a major, but not complete, role in target recognition, and reveal that the miR-499 c17 mutation can conditionally affect mRNA target suppression.
Perfect miR-mRNA sequence complementarity is exceedingly rare in animals. 19 Therefore, we examined the consequences of the miR-499 mutation on suppression of luciferase reporters containing partial 3Јuntranslated regions of 3 bioinformatically defined miR-499 target mRNAs. Because Tar-getScan relies heavily on seed sequence complementarity to predict target mRNAs, each of the predicted miR-499 target mRNAs, Sox6, Pdcd4, and Skil, had multiple binding sites with perfect seed sequences. Therefore, and as anticipated from the artificial reporter assays above, functional differences induced by the c17 mutation were modest. Nevertheless, Sox6 and Pdcd4 were more effectively suppressed by wild-type miR-499, whereas Skil exhibited no preference ( Figure 2B ). While in vitro reporter studies do not precisely reproduce in vivo miR targeting because of differences in mRNA structure and absence of coregulatory miRs, 20,21 these results show that the miR-499 3Ј mutation modifies suppression of a subset of target mRNAs.
miR-499 c17 Mutation Alters in Vivo and Cardiac Function and mRNA Targeting
The miR-499 is up-regulated in human and experimental heart disease 9,22 and confers a pathological phenotype when forcibly expressed in cardiac myocytes. 10 We created transgenic mice to explore whether the modest differences in suppression of some mRNA targets by mutant miR-499 c17 altered normal in vivo cardiac mRNA targeting, and therefore the cardiac phenotype. On the basis of previous results in which unbiased RISC-sequencing identified cardiac miR-133 mRNA targets without perfect seed sequence complementarity, 13 we posited that the 3Ј miR-499 mutation might have greater impact on these "weaker" (and bioinformatically overlooked) mRNA targets. This notion was supported by our observation that, despite expressing at slightly greater levels in mouse myocardium than its wild-type analog ( Figure 3A ), miR-499 c17 favorably impacted the characteristic progressive cardiomyopathy induced by miR-499 overexpression: in comparison with wild-type miR-499 expressing hearts, those expressing mutant miR-499 developed less severe cardiac remodeling ( Figure 3B ) and impairment of ejection performance ( To better understand the relationship between phenotype and function in wild-type and mutant miR-499 mice, we used agnostic whole-genome approaches to compare cardiac mRNA targeting to the RISC, and to define primary and secondary effects of the miR-499 c17 mutant on steady state cardiac mRNA levels. 13, 23 The mRNA content of mouse heart RISCs genetically programmed with wild-type or c17 mutant miR-499 was assayed in 4-week-old mice, at an age when heart function is still normal (thus avoiding potentially confounding effects of the age-dependent cardiomyopathy). A total of 109 mRNAs were enriched in miR-499 programmed cardiac RISCs, representing cardiac-expressed mR-NAs targeted by miR-499. Of these, 42 were preferentially targeted by c17 mutant miR-499, 8 were preferentially targeted by wild-type miR-499, and 59 showed no preference (Online Table II ). Unsupervised hierarchical clustering of RISC-enriched miR-499 target mRNAs was Ͼ80% accurate in grouping the mice according to genotype ( Figure 4A ). Gene-ontology analysis showed that both wild-type and mutant c17 miR-499 mRNA targets segregated into functional categories linked to cell signaling and transcriptional regulation ( Figure 4B ).
The miRs act primarily by destabilizing their mRNA targets, thus decreasing steady state mRNA levels. 24, 25 Twelve target mRNAs were down-regulated preferentially by mutant miR-499 c17, 1 mRNA was down-regulated preferentially by wild-type miR-499, and 24 miR-499 target mR-NAs were decreased by both ( Figure 5A) . A small number of miR-499 RISC-targeted mRNAs showed increased steady state levels, as described for atypical miR-target interactions 26 ( Figure 5A ). Concordance of mRNA down-regulation and RISC enrichment by the respective miR-499 was 68% for wild-type miR-499 and 94% for miR-499 c17 hearts.
miR-499 c17 Mutation Alters Myocardial Protein Levels
The major function of myomiRs is regulating myosin isoform levels in response to stress or hormonal factors. 6, 7 Yet, neither of the myomiR-regulated myosin heavy chain mRNAs is a direct target of any myomiR. This is an example of indirect targeting, and reflects secondary and tertiary consequences of miRs acting on their direct mRNA targets. 20 We used 2-dimensional differential in-gel electrophoresis (DiGE) 16 of mouse myocardium to examine the proteomes of Ϸ8-weekold wild-type and mutant c17 miR-499 expressing hearts, in RISC score was 81% accurate in grouping the mice according to genotype, and 86% accurate in differentiating between wild-type miR-499 and mutant miR-499 c17-expressing hearts. Blue shading, lower RISC scores (RISCome content/transcriptome content); red shading, higher RISC scores. B, Gene ontology classification of miR-499 RISC-enriched mRNAs. Upper: 109 miR-499 mRNA targets. Bold type indicates overrepresented categories. Lower: Functional classification of miR-499 target mRNAs that did not discriminate between wild-type miR-499 and mutant miR-499 (on the left) or that showed a preference for mutant miR-499 (on the right). comparison with nontransgenic controls. Although DiGE is an agnostic measure of cardiac protein content, it preferentially examines the more highly expressed portion of the proteome and cannot detect poorly expressed direct miR targets. 20 Of 56 regulated spots identified by mass spectroscopy, 41 proteins were coregulated by wild-type and mutant miR-499, 9 proteins were preferentially regulated by wildtype miR-499, and 6 proteins were preferentially regulated by mutant c17 miR-499 ( Figure 5B , Online Table III) .
miR-499 has been implicated as an indirect regulator of protein phosphorylation by suppressing the phosphatase calcineurin. 27 We did not find direct or indirect regulation of calcineurin mRNA in either wild-type or mutant miR-499 programmed hearts. However, we did find evidence of indirect effects on myocardial phosphoprotein content, providing mechanistic insight into the salutary effects of the c17 mutation on the cardiomyopathy induced by increased miR-499 expression. Myosin-binding protein C (MyBP-C) is a potent modifier of cardiac contractility; its effects are regulated through phosphorylation by several cardiac protein kinases. 28 MyBP-C phosphorylation, indicated as a leftward shift toward lower pH, 16 is increased in wild-type miR-499 expressing hearts, but not in mutant c17 miR-499 expressing hearts ( Figure 5C and 5D ). Increased MyBP-C phosphorylation is a biochemical signature of cardiac pathology. 16 Although protein kinases and phosphatases were not identified as direct miR-499 targets, the alpha subunits of G13 and Go and other cell-signaling factors are (Online Table II) , and modulate downstream protein kinase activity. 29 Thus, differential effects of mutant c17 miR-499 on its direct and indirect mRNA targets can explain observed differences in protein expression, processing, and end-organ phenotype.
The Structural Basis for Differential mRNA Targeting by Wild-Type and c17 Mutant miR-499
To better grasp the consequences of miR sequence variation on miR-mRNA interactions, we defined the characteristics of miR-499 binding sites within its antithetically regulated mRNA targets. Approximately one third of these sites exhibited perfect miR-499 seed sequence complementarity ( Figure  6A) ; the influence of nt 17 on miR-499 target binding was greater in the majority of mRNA sites wherein seed sequence pairing was imperfect, 3, 30 with g corresponding to nt 17 in 56% of miR-499 c17 target sites, versus 20% of wild-type miR-499 u17 target sites (Pϭ0.002; Figure 6A , top row). By comparison, nt 17 had little impact on target sites having perfect seed sequence complementarity ( Figure 6A, bottom  row) . Thus, the probability of miR-499/mRNA pairing is interactively determined by sequence complementarity at both ends of the duplex.
To understand the sequence determinants of miR-499 target recognition, we engineered a complete series of miR-499 target site mutations and compared efficiency of target suppression by wild-type and c17 mutant miR-499 ( Figure  6B ). Target suppression by wild-type miR-499 was most compromised by nucleotide mismatches at the 5Ј end of the miR, affecting nt 3 through 5 of the seed sequence. Single target site mismatches corresponding to nt 6 to 16 in the midregion of the miR-mRNA duplex retained Ϸ70% of wild-type suppression, and target site mutations complementary to the 5Ј end of the miR (between nt 17 and 21) had little effect on target suppression ( Figure 6B, white bars) . In contrast, target site mismatches corresponding to nt 2 through 7 severely impaired or completely abrogated target suppression by the c17 miR-499 mutant, revealing functional cooperativity between 5Ј and 3Ј nucleotides in the miR-mRNA duplex. Target site mismatches complementary to miR-499 nt 13 and 14 also eliminated target suppression by the c17 miR-mutant ( Figure 6B, black bars) . By comparison, sequence mismatches in the midregion of the duplex, between nt 8 and 12, and those corresponding to miR-499 nt 18 through 21, retained a high level of target suppression by mutant miR-499 c17 (Figure 6B, black bars) . Coexpression of wild-type and mutant c17 miR-499, which simulates heterozygosity in the human subjects wherein the miR-499 mutant was detected, induced intermediate functional phenotypes (Online Figure II) .
Molecular modeling of miR-mRNA hybrid binding energy to target suppression revealed structural diversity of the RNA duplexes that explains differential mRNA targeting by the miR-499 c17 mutant ( Figure 6C and 6D and Online Figure  III) . Single base-pair mismatches within 4 nucleotides of either end of the wild-type miR-499 -mRNA duplex disrupt one end of the miR-mRNA hybrid, effectively truncating the miR while otherwise maintaining continuous miR-mRNA binding ( Figure 6C) ; single base-pair mismatches at any position between nucleotides 6 and 17 produce a localized bulge in the duplex ( Figure 6C ). The c17 miR-499 mutation altered the miR-mRNA interaction in 2 ways: the cooperative interaction between 3Ј and 5Ј base pairs within the duplex exaggerates disruption of miR-mRNA binding when there is a target site mismatch corresponding to nt 2 to 7 ( Figure 6D) , and target site mismatches within 4 nt 5Ј or 2 nt 3Ј of the mutant base produce atypical miR-mRNA duplex configurations that adversely impact target suppression ( Figure 6D ).
Discussion
Here we provide evidence that naturally occurring miR sequence variation can broadly affect miR function, even when the nucleotide mismatch is located far away from the critical 5Ј seed sequence generally considered to drive mRNA target recognition and suppression. Using high-throughput next-generation sequencing, we identified a human mutation in mature miR-499 that alters its mRNA targeting profile and end-organ effects, enhancing contractile function. By comparing myocardial protein levels on 2-dimensional gels, we identified numerous changes in protein expression induced by both wild-type and mutant miR-499 and uncovered differences in protein mobility/phosphorylation induced by the mutant that may reflect its favorable impact on cardiac contraction. Finally, we took advantage of this naturally occurring mutation to interrogate the structural determinants of miR-mRNA pairing. To our knowledge, these studies are the first to establish a functional consequence of 3Ј miR sequence variation and to demonstrate (at least in the mouse model) disease modification by a nonseed sequence miR mutation.
The most important aspect of this work is the finding that mature miR sequence variation outside of the "seed" sequence can have meaningful biological effects. Our results show that nucleotide variation in the 3Ј end of a miR (or of the corresponding mRNA binding site) has less impact when miR and binding site seed sequence complementarity are perfect or nearly so. There is increasing evidence for nonseed sequence miR binding (through "centered pairing" sites, for example, Shin et al 31 ) , and our results show that only approximately one third of in vivo miR-499 mRNA targets have perfect seed sequences. Thus, 3Ј miR sequence variants have the potential to modify the effects of an miR, while retaining its primary functional characteristics. This observation may deserve consideration in human genetic screening as well as when designing long or short miR-targeting molecules.
The conventional approaches of defining mRNA targets of miRs reasonably uses bioinformatics to define a population of candidate mRNA targets, on the basis of sequence complementarity. We found that this approach was not useful to direct comparative studies of wild-type and c17 mutant miR-499 because their seed sequences are identical, and current miR target analysis software emphasizes seed sequence complementarity. Indeed, analysis with the popular TargetScan platform did not predict any differences in wildtype and mutant miR-499 targets. Because our previous RISC-enrichment studies of mouse hearts programmed with miR-133 had revealed a large number of miR targets lacking perfect seed sequences that were not identified as targets by bioinformatics, 32 here we used unbiased RISC profiling to compare the direct mRNA targets of wild-type and mutant miR-499. Whereas many mRNAs were recruited to cardiac is plotted over a range of 0% to 100%, and minimum free energy of hybridization (mfe) between Ϫ18 and Ϫ38 kcal/mol, both as a function of target site mutation for wild-type miR-499 (u17; left) or mutant miR-499 (c17, right); gray shading indicates miR-499 seed sequence. Optimal miR-499 -mRNA duplex structures for target site mutants are schematically depicted above the plots; the green strand is miR-499 and black strand is mRNA target.
RISCs by both miR-499s, a minority of RISC-enriched mRNAs showed a preference for one or the other miR-499. Posthoc analysis of complementary sequences in the 3ЈUTRs of these biologically defined preferential targets revealed the role of binding site complementation corresponding to the mutant miR nucleotide in selective targeting.
Another novel aspect of these studies is incorporation of RNA duplex structure information into the data analysis. Our results show how miR-mRNA binding energy, mRNA suppression, and miR-mRNA duplex structure are interrelated. The interactions between 5Ј seed and 3Ј nonseed sequence mismatches that we identified were not predicted by RNA hybrid software, and were identified only by modeling structure and binding energy to luciferase suppression data. Translating these types of in vitro reporter data to the in vivo condition will require not only extrapolation of information about RNA duplex configuration, but also on secondary mRNA 3ЈUTR structure that may either limit or facilitate binding of individual mRNA binding sites to miR/RISCs. These considerations are particularly well illustrated by the 3ЈUTR structure of miR-499 binding domains within its thoroughly validated mRNA target, Sox6 (Online Figure IV) .
In conclusion, we describe mechanisms for, and consequences of, altered mRNA targeting by a rare 3Ј human miR-499 mutant. Because miR-499 is highly expressed in cardiac tissue, is up-regulated in human heart failure, and is sufficient to cause heart failure in mice, we postulated that misregulation of even a fraction of normal miR-499 targets by the c17 mutant might significantly impact cardiac function. The only known prior example linking functional miR mutations to a human disorder are seed-sequence mutations of miR-96 in familial hearing loss. 33 The current results suggest that extra-seed sequence miR mutations may act as disease modifiers by altering the pattern of mRNA suppression for targets lacking perfectly complementary seed sequences. Our findings emphasize the need to comprehensively and agnostically define miR-mRNA interactions and miR-regulated protein expression in proper biological context, accounting for endogenous mRNA expression patterns and cooperativity with other regulatory factors. The insights derived from in vivo studies of miR-mRNA interactions in relevant tissues, and from integrating molecular modeling with biological data, provide a different perspective on the consequences of miR mutations and suggest opportunities for better defining the individual genetic determinants of disease and future miR-based therapeutics. 1, 34 
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What New Information Does This Article Contribute?
• We discovered a rare human miR-499 mutation at nucleotide 17 (of 21), well outside of the seed region thought to determine miR-mRNA pairing. • In comparison with wild-type miR-499, the mutant reduced in vitro suppression of known miR-499 targets, altered in vivo recruitment of cardiac mRNAs to RNA-induced silencing complexes, and modified the cardiac phenotype. • The structural basis for dysfunction induced by the miR-499 mutation is unstable miR-mRNA duplex configurations.
Here we describe and characterize a new mutation in the cardiac-expressed microRNA, miR-499. MicroRNA mutations are rare in available human genome databases. We postulated that this rarity relates to the primary function of microRNAs, which is to bind to specific target mRNAs and orchestrate their destruction. Altered nucleotide sequence would alter miR-mRNA binding and alter the profile of mRNA targeting. Because microRNAs target many different mRNAs, and each of these mRNA products can have secondary and tertiary end-organ effects, the consequences of microRNA mutations are potentially quite broad. On the other hand, if miR-mRNA interactions are driven largely by 5Ј seed sequences (nt 2-8) (as is commonly believed), then only seed sequence mutations should have significant effects. The current studies provide the first example of a nonseed sequence human microRNA mutation that alters normal microRNA function. We show that the substitution of wildtype u17 for c17 alters in vivo cardiac mRNA recognition, we reveal that differential mRNA recognition is driven by binding site complementarity corresponding to miR nt 17, and we describe the broad and unpredictable consequences of this mutation. These findings should stimulate further discovery of human miR mutations and define a comprehensive platform for their analysis.
